肿瘤与血栓精要.ppt

Young AM et al. Lancet 2009;373:567 WARP: 预防性用华法林不能降低癌症患者 与导管相关的血栓形成 Bleeding and Raised INR Warfarin 评价 剂量评价 No warfarin (n=404) Warfarin (n=408) 相关风险 (95% CI, p value) 固定剂量 warfarin (n=471) 调节剂量 warfarin (n=473) 相关风险(95% CI, p value) Major bleeding and no reported raised INR 1 (1%) 3 (1%) - 5 (1%) 7 (1%) - Major bleeding and raised INR 0 4 (1%) - 2 (1%) 9 (2%) - Total major bleeding 1 (1%) 7 (2%) 6.93 (0.85-56.08, 0.07) 7 (1%) 16 (3%) 2.28 (0.95-5.48, 0.09) Moderate and severe raised INR and no major bleeding 0 3 (1%) - 1 (1%) 12 (3%) - Minor bleeding 1 (1%) 14 (3%) - 21 (4%)